홈
oii****
님 답변
답변일
12/30/2023 9:05:41 AM
Handbook of Clinical Neurology, Elsevier 출판사, 2013
Neurofibromatosis type 1 (NF1): diagnosis and management
Rosalie E Ferner 1, David H Gutmann
Advances in molecular biology and mouse models of disease have enhanced our understanding of the pathogenesis of NF1 complications and facilitated targeted therapy. Progress has been made in developing robust clinical and radiological outcome measures and clinical trials are underway for children with learning difficulties and for individuals with symptomatic plexiform neurofibromas.
These basic scientific insights have resulted in the identification of several new drug therapies, including rapamycin and Gleevec, which are now in clinical trial for plexiform neurofibroma (Robertson et al., 2012). The availability of robust preclinical GEM models also provides an efficient platform to …로 기술되어 있습니다. 자세한 것은 다니시는 병원의 의사선생님과 긴밀히 상담해 보시는 것이 좋을 듯 합니다.
위의 논문은 https://pubmed.ncbi.nlm.nih.gov/23931823/ 로 가시면 full text 논문을 구입하실 수 있습니다.
Neurofibromatosis type 1 (NF1): diagnosis and management
Rosalie E Ferner 1, David H Gutmann
Advances in molecular biology and mouse models of disease have enhanced our understanding of the pathogenesis of NF1 complications and facilitated targeted therapy. Progress has been made in developing robust clinical and radiological outcome measures and clinical trials are underway for children with learning difficulties and for individuals with symptomatic plexiform neurofibromas.
These basic scientific insights have resulted in the identification of several new drug therapies, including rapamycin and Gleevec, which are now in clinical trial for plexiform neurofibroma (Robertson et al., 2012). The availability of robust preclinical GEM models also provides an efficient platform to …로 기술되어 있습니다. 자세한 것은 다니시는 병원의 의사선생님과 긴밀히 상담해 보시는 것이 좋을 듯 합니다.
위의 논문은 https://pubmed.ncbi.nlm.nih.gov/23931823/ 로 가시면 full text 논문을 구입하실 수 있습니다.
